Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F12%3A12197" target="_blank" >RIV/00216208:11110/12:12197 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/12:12197
Result on the web
<a href="http://dx.doi.org/10.1177/1352458511435105" target="_blank" >http://dx.doi.org/10.1177/1352458511435105</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
Original language description
Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS). Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV). We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML. Natalizumab treatment duration and prior use of immunosuppressive therapies are established risk factors for development of PML in natalizumab-treated patients. With the development of a reliable and validated assay for detection of antibodies in patients with MS directed against JCV, it is now possible to identify persons who are carriers of JCV. The availability of this assay provides an additional option for risk stratification of PML in patients using or considering natalizumab therapy. Recommendations for clinical management of patients w
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—
Result continuities
Project
—
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Multiple Sclerosis Journal
ISSN
1352-4585
e-ISSN
—
Volume of the periodical
18
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
143-152
UT code for WoS article
000299903700006
EID of the result in the Scopus database
—